134 related articles for article (PubMed ID: 25487528)
1. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis.
Buzzard KA; Meyer NJ; Hardy TA; Riminton DS; Reddel SW
Muscle Nerve; 2015 Aug; 52(2):204-10. PubMed ID: 25487528
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis.
Nagappa M; Netravathi M; Taly AB; Sinha S; Bindu PS; Mahadevan A
J Clin Neurosci; 2014 Nov; 21(11):1909-14. PubMed ID: 25043165
[TBL] [Abstract][Full Text] [Related]
3. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.
Gomez-Figueroa E; Garcia-Trejo S; Bazan-Rodriguez L; Cervantes-Uribe R; Chac-Lezama G; López-Hernández JC; Vargas-Cañas S
J Neurol; 2020 Mar; 267(3):674-678. PubMed ID: 31720821
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide.
Drachman DB; Jones RJ; Brodsky RA
Ann Neurol; 2003 Jan; 53(1):29-34. PubMed ID: 12509845
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Lauque D; Puéchal X; Letellier P; Delaval P; Cordier JF; Guillevin L;
Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
7. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
Lau AY; Chan AY; Mok VC
Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment administration of cyclophosphamide in membranous nephropathy.
Dede F; Ayili D; Sahiner S
J Nephrol; 2008; 21(4):560-5. PubMed ID: 18651546
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
[TBL] [Abstract][Full Text] [Related]
10. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.
Munyangango EM; Le Roux-Villet C; Doan S; Pascal F; Soued I; Alexandre M; Heller M; Lièvre N; Aucouturier F; Caux F; Laroche L; Prost-Squarcioni C
Br J Dermatol; 2013 Feb; 168(2):381-90. PubMed ID: 22963186
[TBL] [Abstract][Full Text] [Related]
11. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.
Lin PT; Martin BA; Weinacker AB; So YT
Muscle Nerve; 2006 Mar; 33(3):433-5. PubMed ID: 16116645
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
13. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
14. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
Mok CC; Ho CT; Siu YP; Chan KW; Kwan TH; Lau CS; Wong RW; Au TC
Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.
De Feo LG; Schottlender J; Martelli NA; Molfino NA
Muscle Nerve; 2002 Jul; 26(1):31-6. PubMed ID: 12115946
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease.
Schmidt KJ; Fellermann K; Wellhöner P; Weitz G; Homann N; Herrlinger K; Lehnert H; Ludwig D; Büning J
Aliment Pharmacol Ther; 2009 Jun; 29(12):1230-9. PubMed ID: 19302074
[TBL] [Abstract][Full Text] [Related]
17. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
18. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
[TBL] [Abstract][Full Text] [Related]
20. Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome.
Bircan Z; Kara B
Pediatr Int; 2003 Feb; 45(1):65-7. PubMed ID: 12654072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
